BioSpace News Archive

Sintalica Bioscience Corp. (“Sintalica” or the “Company”), a drug discovery company focused on breakthrough treatments for neuroinflammatory disorders, today announced that the Company has achieved two important milestones through the University of Messina (the “University”).

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Needham Virtual Neuroscience Forum on Wednesday, March 15, 2023 at 10:00 a.m. ET.

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2022.

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper) today announced results for the fiscal year ended December 31, 2022, and provided a business update.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it will present at the Oppenheimer 33rd Annual Healthcare Conference.

Geisinger Health Plan and the Medacta Group SA, a Swiss company specializing in sustainable solutions for joint replacement, sports medicine and spine surgeries, announced the first lifetime guarantee for a lumbar spinal fusion surgery.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 10:45 a.m. Eastern Time on Wednesday, March 15 2023 in Miami.

KORU Medical Systems, Inc., a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, reported financial results for the fourth quarter and full year ended December 31, 2022.